305 related articles for article (PubMed ID: 25746910)
1. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus: a risk factor in patients with Graves' orbitopathy.
Kalmann R; Mourits MP
Br J Ophthalmol; 1999 Apr; 83(4):463-5. PubMed ID: 10434871
[TBL] [Abstract][Full Text] [Related]
3. Graves' disease in subjects with type 1 diabetes mellitus: a prevalence study in western Sicily (Italy).
Greco D; Pisciotta M; Gambina F; Maggio F
Prim Care Diabetes; 2011 Dec; 5(4):241-4. PubMed ID: 21704580
[TBL] [Abstract][Full Text] [Related]
4. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
5. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
6. Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy.
Lanzolla G; Puccinelli L; Giudetti M; Comi S; Menconi F; Maglionico MN; Posarelli C; Figus M; Marcocci C; Marinò M
J Endocrinol Invest; 2023 Feb; 46(2):337-344. PubMed ID: 36030301
[TBL] [Abstract][Full Text] [Related]
7. Predictive Model for Graves' Ophthalmopathy in Patients with New-Onset Graves' Disease.
Ahn HY; Lee J; Lee JK
Thyroid; 2022 Dec; 32(12):1559-1567. PubMed ID: 36128837
[No Abstract] [Full Text] [Related]
8. [Graves' orbitopathy].
Balázs C
Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
[TBL] [Abstract][Full Text] [Related]
9. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
[TBL] [Abstract][Full Text] [Related]
10. Serum selenium status in Egyptians patients who had Graves' disease with and without ophthalmopathy.
Hasanin GA; Mohamed MS; Maher MM; Ahmed AM; ALi HM; Mansour HK
Egypt J Immunol; 2024 Jan; 31(1):133-142. PubMed ID: 38224470
[TBL] [Abstract][Full Text] [Related]
11. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for Graves' Orbitopathy in surgical patients-Results of a 10-year retrospective study with review of the literature.
Tabriz N; Gruben A; Uslar V; Weyhe D
Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00210. PubMed ID: 33532627
[TBL] [Abstract][Full Text] [Related]
13. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy.
Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA
Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035
[TBL] [Abstract][Full Text] [Related]
14. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.
Hou J; Tang Y; Chen Y; Chen D
Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341
[TBL] [Abstract][Full Text] [Related]
15. Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed graves' disease.
Lee J; Kang J; Ahn HY; Lee JK
Eye (Lond); 2023 Nov; 37(16):3382-3391. PubMed ID: 37041348
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for development or deterioration of Graves' ophthalmopathy.
Stan MN; Bahn RS
Thyroid; 2010 Jul; 20(7):777-83. PubMed ID: 20578901
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, presentation and clinical evolution of Graves' disease in children and adolescents with type 1 diabetes mellitus.
Lombardo F; Messina MF; Salzano G; Rabbone I; Lo Presti D; Calcaterra V; Aversa T; De Luca F; Wasniewska M
Horm Res Paediatr; 2011; 76(4):221-5. PubMed ID: 21811047
[TBL] [Abstract][Full Text] [Related]
18. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
19. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
20. miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.
Craps J; Joris V; Baldeschi L; Daumerie C; Camboni A; Buemi A; Lengelé B; Behets C; Boschi A; Mourad M; Many MC; Dessy C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
